Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0594 dose-ranging study in overactive bladder
2005-006201-12Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of serlopitant in overactive bladder (OAB) (5 arms), sponsored by Merck & Co. Primary endpoints: Reduction in average number of daily micturitions and Incidence of dry mouth. Started Sep 2007; status: terminated.
02
Drugs
serlopitant
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-006201-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006201-12.